Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial.

Schuurhuizen CSEW, Braamse AMJ, Beekman ATF, Cuijpers P, van der Linden MHM, Hoogendoorn AW, Berkhof H, Sommeijer DW, Lustig V, Vrijaldenhoven S, Bloemendal HJ, van Groeningen CJ, van Zweeden AA, van der Vorst MJDL, Rietbroek R, Tromp-van Driel CS, Wymenga MNW, van der Linden PW, Beeker A, Polee MB, Batman E, Los M, van Bochove A, Brakenhoff JAC, Konings IRHM, Verheul HMW, Dekker J.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):911-920. doi: 10.6004/jnccn.2019.7285.

PMID:
31390590
2.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

3.

Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.

Peters GJ, Smid K, Meijer E, van Groeningen CJ, Leon LG.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):595-603.

PMID:
27906628
4.

Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.

Kroep JR, van Werkhoven E, Polee M, van Groeningen CJ, Beeker A, Erdkamp F, Weijl N, van Bochove A, Erjavec Z, Kapiteijn E, Stiggelbout AM, Nortier HW, Gelderblom H.

J Geriatr Oncol. 2015 Jul;6(4):307-15. doi: 10.1016/j.jgo.2015.05.004. Epub 2015 Jul 17.

5.

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone.

Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HM.

BMC Palliat Care. 2014 Aug 20;13:42. doi: 10.1186/1472-684X-13-42. eCollection 2014.

6.

[Brain metastases occurring more often in colorectal carcinoma].

Werter IM, van der Stap D, Bertelsmann FW, van Groeningen CJ.

Ned Tijdschr Geneeskd. 2014;158:A7256. Dutch.

PMID:
24735811
7.

A pubic mass.

Möhlmann MC, Rustemeijer C, van Groeningen CJ, Stigter DA.

Neth J Med. 2012 Oct;70(8):374-8. No abstract available.

8.

Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.

Mauritz R, Giovannetti E, Beumer IJ, Smid K, Van Groeningen CJ, Pinedo HM, Peters GJ.

Clin Colorectal Cancer. 2009 Jul;8(3):146-54. doi: 10.3816/CCC.2009.n.024.

PMID:
19632929
9.

A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.

van Riel JM, Peters GJ, Mammatas LH, Honeywell RJ, Laan AC, Ruyter R, van den Berg FG, Giaccone G, van Groeningen CJ.

Eur J Cancer. 2009 Sep;45(14):2519-27. doi: 10.1016/j.ejca.2009.05.025. Epub 2009 Jun 24.

PMID:
19556122
10.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

11.

Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.

Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, Giaccone G, Peters GJ.

Ann Oncol. 2009 Jan;20(1):182-7. doi: 10.1093/annonc/mdn543. Epub 2008 Aug 12.

PMID:
18701427
12.

[A patient with very high serum level of human chorionic gonadotrophin; the diagnosis is not always a germ-cell tumour].

van der Vliet HJ, Lefesvre P, van Groeningen CJ.

Ned Tijdschr Geneeskd. 2008 Mar 22;152(12):705-9. Dutch.

PMID:
18438068
13.

Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma.

Beeker A, Boven E, Lefesvre P, Golding R, van Groeningen CJ.

Int J Clin Oncol. 2008 Feb;13(1):71-3. doi: 10.1007/s10147-007-0689-3. Epub 2008 Feb 29.

PMID:
18307023
14.

Evaluation of a face-to-face psychosocial screening intervention for cancer patients: acceptance and effects on quality of life.

Bramsen I, van der Linden MH, Eskens FJ, Bijvank EM, van Groeningen CJ, Kaufman HJ, Aaronson NK.

Patient Educ Couns. 2008 Jan;70(1):61-8. Epub 2007 Nov 7.

PMID:
17997260
15.

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.

Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A, van der Vijgh WJ, van Groeningen CJ.

Br J Cancer. 2007 Oct 22;97(8):1084-9. Epub 2007 Oct 16.

16.

Tonsillar metastasis of oesophageal adenocarcinoma.

Struijs B, de Bree R, van Groeningen CJ, Mooi WJ, Leemans CR.

Eur Arch Otorhinolaryngol. 2008 Jan;265(1):127-9. Epub 2007 Jul 27.

17.

Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.

Smorenburg CH, van Groeningen CJ, Meijer OW, Visser M, Boven E.

Neth J Med. 2007 Apr;65(4):132-6.

18.

Bilateral adrenal enlargement with an unexpected diagnosis.

van den Heiligenberg SM, van Groeningen CJ.

Eur J Intern Med. 2007 May;18(3):249-50.

PMID:
17449402
19.

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.

Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ.

Int J Cancer. 2007 Jun 15;120(12):2609-12.

20.

Electroporation therapy in soft tissue sarcoma: a potentially effective novel treatment.

de Bree R, Tijink BM, van Groeningen CJ, Leemans CR.

Sarcoma. 2006;2006:85234.

21.

Analysis of deoxycytidine accumulation in gemcitabine treated patients.

Honeywell R, van Groeningen CJ, Laan AC, Strocchi E, Ruiter R, Giaccone G, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1225-32.

PMID:
17065096
22.

The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry.

Honeywell R, Laan AC, van Groeningen CJ, Strocchi E, Ruiter R, Giaccone G, Peters GJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 1;847(2):142-52. Epub 2006 Oct 23.

PMID:
17056304
23.

Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.

Savonije JH, van Groeningen CJ, van den Broek WJ, Rentinck ME, Corstens FH, Gundy C, Giaccone G, Marx JJ.

Cancer Invest. 2006 Oct;24(6):562-6.

PMID:
16982459
24.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.

Clin Cancer Res. 2006 Mar 15;12(6):1760-7.

25.

Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.

Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ.

Cancer Chemother Pharmacol. 2006 Oct;58(4):509-16. Epub 2006 Mar 7.

PMID:
16523337
28.

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L; EORTC Genito-Urinary Cancer Group.

Eur J Cancer. 2006 Jan;42(1):50-4. Epub 2005 Dec 5.

PMID:
16330205
29.

No evidence of gemcitabine accumulation during weekly administration.

de Lange SM, van der Born K, Kroep JR, Jensen HA, Pfeiffer P, Cleverly A, van Groeningen CJ, Peters GJ.

Eur J Clin Pharmacol. 2005 Dec;61(11):843-9. Epub 2005 Nov 10.

PMID:
16283278
30.

Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G.

Ann Oncol. 2006 Jan;17(1):35-42. Epub 2005 Oct 26.

PMID:
16251201
31.

A phase I study of monohydroxyethylrutoside in healthy volunteers.

Willems AM, Bruynzeel AM, Kedde MA, van Groeningen CJ, Bast A, van der Vijgh WJ.

Cancer Chemother Pharmacol. 2006 May;57(5):678-84. Epub 2005 Sep 1.

PMID:
16136309
32.

Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.

Codacci-Pisanelli G, Pinedo HM, Lankelma J, Van Groeningen CJ, Van Kuilenburg AB, Van Gennip AH, Peters GJ.

J Chemother. 2005 Jun;17(3):315-20.

PMID:
16038526
33.

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, Giaccone G.

Eur J Cancer. 2005 Jul;41(11):1560-9.

PMID:
15953714
34.

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.

Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G.

Br J Cancer. 2005 May 9;92(9):1636-43.

35.

Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach.

Peters GJ, Smorenburg CH, Van Groeningen CJ.

J Chemother. 2004 Nov;16 Suppl 4:25-30. Review.

PMID:
15688605
36.

Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.

Mauritz R, Schwabe W, Haeusler P, Noordhuis P, Smid K, McLeod HL, Behnke D, van Groeningen CJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1471-4.

PMID:
15571279
37.

Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients.

Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, van Groeningen CJ, Pinedo HM, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1381-4.

PMID:
15571263
38.

FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer.

Croles N, Smorenburg CH, van Groeningen CJ, Giaccone G, Boven E.

Neth J Med. 2004 Jul-Aug;62(7):242-5.

39.

Carcinomatous meningitis in cancer of the uterine cervix.

Rentinck ME, Schrijver HM, Kneppers E, Zijlmans JC, van Groeningen CJ.

J Neurooncol. 2004 Oct;70(1):87-90. Review.

PMID:
15527113
40.

The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.

Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JH.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4072-6.

41.

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.

Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ.

Ann Oncol. 2004 Jul;15(7):1025-32.

PMID:
15205195
42.

Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.

De Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G.

Ann Oncol. 2004 Mar;15(3):484-8.

PMID:
14998853
43.

Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.

Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ.

Ann Oncol. 2004 Feb;15(2):230-5.

PMID:
14760114
44.

Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.

van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G.

Ann Oncol. 2004 Jan;15(1):59-63.

PMID:
14679121
45.

Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods.

Kroep JR, Van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF, Bloemena E, Hoekstra CJ, Golding RP, Twisk JW, Peters GJ, Pinedo HM, Lammertsma AA.

Mol Imaging Biol. 2003 Sep-Oct;5(5):337-46.

PMID:
14630513
46.

Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

ten Bokkel Huinink WW, van Groeningen CJ, Voest EE, Peters WG, Keizer HJ, de Witte JH.

Neth J Med. 2003 Jul;61(7):249-56.

47.

Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.

Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen CJ, Vandertop WP, Slotman BJ, Postma TJ.

J Clin Oncol. 2003 Oct 1;21(19):3559-65. Epub 2003 Aug 11.

PMID:
12913097
48.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ.

Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. Epub 2003 May 9.

PMID:
12739060
49.

Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.

van der Wilt CL, Kroep JR, Loves WJ, Rots MG, Van Groeningen CJ, Kaspers GJ, Peters GJ.

Eur J Cancer. 2003 Mar;39(5):691-7.

PMID:
12628850
50.

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ.

Mol Cancer Ther. 2002 Apr;1(6):371-6.

Supplemental Content

Loading ...
Support Center